Skip to main content
SpringerLink
Log in

Hypophysen-und Hypothalamushormone

  • Chapter
Arzneiverordnungs-Report 2007

  • 559 Accesses

Auszug

Hauptvertreter der Hypophysen und Hypothalamushormone sind Wachstumshormon, Somatostatin, Gonadotropinpräparate und Vasopressinanaloga. Wachstumshormonpräparate haben ihre bisherige Aufwärtsentwicklung fortgesetzt und sind mit einem Umsatz von 157 Mio. € die umsatzstärkste Gruppe der Hypophysen und Hypothalamushormone. An zweiter Stelle folgt Somatostatin (56 Mio. €), während Follitropinpräparate mit 43 Mio. € nach den geänderten Kostenregelungen für die künstliche Befruchtung seit 2004 deutlich seltener eingesetzt werden. Die Verordnungen der Vasopressinanaloga für die Behandlung des zentralen Diabetes insipidus blieben konstant.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Collins J (2003): A turbulent area. Fertil Steril 80: 1117–1120.

    Article  PubMed  Google Scholar 

  • De Mouzon J, Allavena E, Schmitt C, Frappe M (2004): In vitro fertilization in France: economic aspects and influence of the gonadotropin choice (urinary vs. recombinant) on cost. Gynecol Obstet Fertil 32: 508–518. [Article in French].

    Article  PubMed  Google Scholar 

  • Frydman R, Howies CM, Truong F (2000): A double-blind, radomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists. Hum Reprod 15: 520–525.

    Article  PubMed  CAS  Google Scholar 

  • International Recombinant Human Chorionic Gonadotropin Study Group (2001): Induction of ovulation in World Health Organization group II anovulatory women undergoing follicular stimulation with recombinant human follicle-stimulating hormone: a comparison of recombinant human chorionic gonadotropin (rhCG) and urinary hCG. Fertil Steril 75: 1111–1118.

    Article  Google Scholar 

  • Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber AM, Hoffman AR (2007): Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 146: 104–115.

    PubMed  Google Scholar 

  • Ludwig M, Bühler K, Diedrich K, Felberbaum RE, Rabe T (2004): Wirksamkeit von rekombinantem humanem FSH im Vergleich zu urinärem hMG nach Downregulation im langen Protokoll Eine Analyse von 24.764 ART-Zyklen in Deutschland: J Reproduktionsmed Endokrinol 1: 284–288.

    Google Scholar 

  • Mochtar M, Van der Veen, Ziech M, van Wely M (2007): Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev. 2007 Apr 18; (2): CD005070.

    Google Scholar 

  • National Institute for Clinical Excellence (NICE) (2002): Guidance on the use of human growth hormone (somatropin) in children with growth failure. Technology Appraisal No. 42. Internet: www.nice.org.uk/page.aspx?o= TA042guidance

    Google Scholar 

  • National Institute for Clinical Excellence (NICE) (2003): Human growth hormone (somatropin) in adults with growth hormone deficiency. Technology Appraisal 64. Internet: www.nice.org.uk/page.aspx?o=TA064guidance

    Google Scholar 

  • Savage MO, Drake WM, Carroll PV, Monson JP (2004): Transitional care of GH deficiency: when to stop GH therapy. Eur J Endocrinol 151Suppl 1: S61–65.

    Article  PubMed  CAS  Google Scholar 

  • Striegel H, Simon P (2007): Doping: High-Tech-Betrug im Sport. Internist: 2007 Apr 11; [Epub ahead of print]

    Google Scholar 

  • Van Wely M, Byram N, van der Ween F (2003): Recombinant FSH in alternative doses or versus urinary gonadotrophins for ouvlation induction in subfertility aossociated with polycystic ovary syndrome: a systematic review based on a Cochrane review. Hum Reprod 18: 1143–1149.

    Article  PubMed  Google Scholar 

  • Van Wely M, Yding Andersen C, Bayram N, van der Veen F (2005): Urofollitropin and ovulation induction. Treat Endocrinol 4: 155–165.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Prof. Dr. med. Ulrich Schwabe

Authors
  1. Prof. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK Schleswig-Holstein Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Schwabe, U. (2008). Hypophysen-und Hypothalamushormone. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2007. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72548-0_30

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-72548-0_30

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-72547-3

  • Online ISBN: 978-3-540-72548-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation